Physician profile
Marcel J Junqueira
NPI 1831353705
$6,130.44
in general payments reported to CMS, 2019-2025
24 companies · $993 in 2025
The $993 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $897 · 2020: $164 · 2021: $369 · 2022: $2,184 · 2023: $733 · 2024: $791 · 2025: $993.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,436 · Education: $80.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,436.48 |
| Education | $80.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pulmonx Corporation | $1,403.24 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $830.53 | 2019-2025 | Tezspire, Fasenra, Breztri |
| Grifols USA, LLC | $677.24 | 2019-2025 | Prolastin-C Liquid |
| Regeneron Healthcare Solutions, INC. | $646.18 | 2022-2025 | Dupixent |
| Glaxosmithkline, LLC. | $529.09 | 2019-2022 | |
| United Therapeutics Corporation | $441.14 | 2019-2025 | Tyvaso, Tyvaso |
| Actelion Pharmaceuticals US, INC. | $322.55 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Boston Scientific Corporation | $251.09 | 2019-2023 | Watchman Access System, Coredx |
| Genzyme Corporation | $158.45 | 2022-2024 | |
| Penumbra, INC. | $149.87 | 2024 | Indigo System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.00 | 2023 | Ofev |
| Philips North America LLC | $107.88 | 2022-2024 | (Ak6) Vest Therapy |
| Harmony Biosciences LLC | $105.09 | 2022-2023 | Wakix |
| Genentech USA, INC. | $99.99 | 2019 | |
| Veran Medical Technologies, INC. | $74.23 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $37.63 | 2024 | |
| Avadel Cns Pharmaceuticals, LLC | $35.90 | 2024-2025 | Lumryz |
| Jazz Pharmaceuticals INC. | $25.93 | 2022 | |
| Abbvie INC. | $22.22 | 2022 | |
| Advanced Respiratory, INC | $21.08 | 2019 | |
| Mirati Therapeutics, INC. | $21.00 | 2023 | Krazati |
| Biogen, INC. | $15.42 | 2024 | Spinraza |
| Inogen, INC. | $15.30 | 2022 | |
| Resmed Corp | $14.39 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marcel Junqueira listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.